Research programme: MM 151 companion diagnostic - Merrimack Pharmaceuticals
Latest Information Update: 30 Mar 2023
At a glance
- Originator Merrimack Pharmaceuticals
- Class Antibodies; Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Mar 2023 Discontinued - Preclinical for Solid tumours (Diagnosis) in USA (unspecified route)
- 28 May 2018 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA
- 03 Apr 2014 Preclinical trials in Solid tumours (diagnosis) in USA before April 2014 (unspecified route)